Abstract
The humoral immune response to p53 was determined in 54 individuals with colon or breast cancer and 50 healthy subjects, in an attempt to better understand the origin and significance of anti-p53 serum antibodies. The presence of anti-p53 antibodies in serum was determined by enzyme-linked immunosorbent assay using purified recombinant human p53, and results were validated by immunoprecipitation of radiolabelled p53. Immunohistochemical analysis of 28 tumours was performed to detect the accumulation of p53 protein. Antibodies against p53 were significantly more common in patients with colorectal (10 of 42) and breast (2 of 12) cancer than in healthy individuals (2 of 50). They were of both the IgM (7 of 11) and IgG (4 of 11) isotypes. There was no significant difference in prevalence of serum antibodies against p53 with respect to the p53 immunohistochemical status of the tumour or to other pathological features, including the presence of lymph node and distant metastases. These findings provide indirect evidence that, rather than arising as a result of a specific immune response, anti-p53 antibodies in individuals with cancer may represent elevated levels of naturally occurring polyreactive antibodies.
References
Mar 7, 1977·Molecular & General Genetics : MGG·G Dougan, D Sherratt
Sep 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·H TowbinJ Gordon
Apr 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·A M DavidoffJ R Marks
Mar 12, 1991·International Journal of Cancer. Journal International Du Cancer·I SorokineM Kohiyama
Jun 6, 1991·Nature·A J LevineC A Finlay
Jul 15, 1990·International Journal of Cancer. Journal International Du Cancer·K Ben-MahrezM Kohiyama
Jan 1, 1989·Annual Review of Immunology·P Casali, A L Notkins
Nov 1, 1989·Immunology Today·P Casali, A L Notkins
Dec 7, 1989·Nature·J M NigroP Devilee
Jul 1, 1989·Analytical Biochemistry·R E BrownK J Hyland
Feb 15, 1987·International Journal of Cancer. Journal International Du Cancer·C Caron de FromentelP May
Aug 15, 1970·Nature·U K Laemmli
May 5, 1981·Journal of Molecular Biology·A SancarW D Rupp
Oct 15, 1982·International Journal of Cancer. Journal International Du Cancer·L V CrawfordR D Bulbrook
May 1, 1995·The Journal of Pathology·A CostaG Torelli
Sep 1, 1995·British Journal of Cancer·J G HoubiersC J Melief
Aug 15, 1994·International Journal of Cancer. Journal International Du Cancer·K AngelopoulouP S Bunting
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J A GreenL Robertson
Apr 1, 1994·The Journal of Experimental Medicine·X DongW H Reeves
Jun 1, 1994·British Journal of Cancer·B MudendaS J Leinster
Aug 1, 1993·Molecular Immunology·S Avrameas, T Ternynck
Feb 1, 1993·Molecular Immunology·M Adib-ConquyT Ternynck
Citations
Dec 18, 2001·International Journal of Cancer. Journal International Du Cancer·R TangL L Hsieh
Nov 23, 2006·Clinical Rheumatology·Yoshihiro MimuraKunihiko Tamaki
Nov 22, 1997·Current Opinion in Immunology·U SahinM Pfreundschuh
Oct 9, 2004·Inflammatory Bowel Diseases·Michele CioffiAnna Maria Molinari
Aug 7, 1999·APMIS. Supplementum·H J Ditzel
Nov 30, 2010·Journal of Oncology·Ettie Piura, Benjamin Piura
Jun 3, 2011·World Journal of Gastroenterology : WJG·Hala E HamoudaWael W Mayah
Jun 30, 2009·Cancer Immunology, Immunotherapy : CII·Miriam ReuschenbachNicolas Wentzensen
Dec 5, 2009·International Journal of Cancer. Journal International Du Cancer·Bozena DobrzyckaMarek Kulikowski
Mar 19, 2016·Scandinavian Journal of Immunology·J XiaH Ye
Mar 10, 1999·British Journal of Cancer·P LennerJ Dillner
Feb 23, 1999·British Journal of Cancer·R SaffroyA Lemoine
Jun 16, 2015·Japanese Journal of Infectious Diseases·Xiao ZhangYi Zeng
Sep 20, 2019·Scandinavian Journal of Immunology·Shuxia LiuXiaohong Han
Feb 14, 2002·British Journal of Haematology·Karen PulfordDavid Y Mason